Skip to main content
Article thumbnail
Location of Repository

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice

By Anna Israyelyan, Vladimir N Chouljenko, Abolghasem Baghian, Andrew T David, Michael T Kearney and Konstantin G Kousoulas
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2004). Herpes simplex virus-based vectors.
    2. (2002). Live viruses in cancer treatment. Oncology
    3. (2003). Oncolytic virotherapy as a novel treatment platform for cancer. Ernst Schering Res Found Workshop
    4. (2002). Oncolytic viruses. Nat Rev Cancer
    5. (2002). Selectively replicating viral vectors. Cancer Gene Ther
    6. (2007). X: Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.